← All Signals

🏥 FDA: K.C. Pharmaceuticals, Inc — Class II

healthcareactionableSource: FDA
85%Confidence
0Views
FDASource
2026-04-17Date

Summary

Redness relief eye drops from K.C. Pharmaceuticals distributed through industrial and pharmacy channels show sterility issues, indicating quality control failures across their entire manufacturing operation. This affects specialized distribution channels including Cintas and AmerisourceBergen.

Actionable: Notify all business customers including Cintas and AmerisourceBergen about potential sterility risks in affected products.

AI Confidence: 85%

Data Points

firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productSterile EYE DROPS REDNESS LUBRICANT (glycerin 0.25% and naphazoline HCl 0.012%), 0.5 fl oz (15 mL) bottles; a) Industrial Eye Relief, Distributed by:

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now